News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Inc. Completes Acquisition of CNS Therapeutics, Inc.


10/2/2012 10:14:21 AM

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has completed its acquisition of CNS Therapeutics, Inc. for approximately $100 million. CNS is a privately held specialty pharmaceuticals company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES